Anika Therapeutics (ANIK) Equity Ratio (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Equity Ratio data on file, last reported at 0.75 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.75, down 4.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.75 (down 4.13% YoY), and the FY2025 annual result was 0.75, down 0.73% from the prior year.
• Equity Ratio slipped to 0.75 in Q1 2026 per ANIK's latest filing, from 0.75 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.84 in Q1 2022 and troughed at 0.75 in Q1 2026.
• A 5-year average of 0.79 and a median of 0.79 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2024: Equity Ratio increased 9.34% in 2022, then dropped 5.7% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.82 in 2022, then decreased by 4.11% to 0.78 in 2023, then declined by 3.16% to 0.76 in 2024, then decreased by 0.73% to 0.75 in 2025, then retreated by 1.0% to 0.75 in 2026.
• Business Quant data shows ANIK's Equity Ratio at 0.75 in Q1 2026, 0.75 in Q4 2025, and 0.77 in Q3 2025.